SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is under pressure amid a selloff in AI infrastructure stocks, as traders focus on its heavy debt, costly financing needs, and whether its contracted demand can support further growth. Bears fear dilution or default, while dip buyers point to the backlog and Nvidia ties; Goldmans upgrade and ARKs buying have not resolved the debate.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is drawing attention amid a steep selloff and negative political sentiment surrounding Trump, with traders pointing to his reported record-low approval and approaching midterms as potential headwinds. The discussion is overwhelmingly bearish, though a few traders describe the decline as a speculative buying opportunity.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Ciphers steep selloff and fresh 52-week lows are driving discussion, with traders focused on dilution and financing concerns around its convertible-note offering, alongside broader scrutiny of AI data-center costs. Bearish reactions criticize management and the share overhang, while bulls point to long-term AI infrastructure demand and data-center contracts as reasons for optimism.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs upcoming Q3 report is the dominant focus, with traders watching for signs that subscriber growth and viewer engagement are holding up, alongside guidance on advertising and margins. The stocks weakness and analyst target cuts have fueled bearish calls for more downside, while some traders see subdued expectations as a setup for a rebound.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Attention is centered on Vicors upcoming quarterly results, with traders pointing to two Q3 growth-guidance increases tied to higher royalties from its Vertical Power Delivery licenses. The community is split between bullish earnings expectations and dip-buying, and concerns about volatility and the stocks history of post-earnings pullbacks.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos steep selloff and an analysts sharp price-target cut are driving discussion, with traders debating whether the decline reflects stretched valuation and resetting growth expectations or broader weakness in defense and drone stocks. Some remain bullish on contract momentum and long-term demand for unmanned systems, while others are frustrated that positive business updates have not steadied the share price.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBios expanded FDA approval of ANKTIVA for papillary-only bladder cancer, alongside favorable long-term bladder data, is the main focus, but shares have sold off despite the positive developments. Traders disagree over whether the decline reflects a sell-the-news move and broader biotech weakness or concerns about valuation, revenue execution, and competition; bullish claims of coordinated short pressure remain speculation.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras shares have fallen sharply to post-IPO lows, with traders pointing to lockup-related share supply, insider selling and a TD Cowen price-target cut as sources of pressure. The conversation is largely bearish over valuation, growth and customer concentration, though some investors see the selloff as an oversold buying opportunity and remain bullish on the companys AI-chip technology.

SK hynix, Inc. engages in the design, manufacture, and sale of semiconductor products. Its products include dynamic random access memory, not-AND flash memory, and multi-chip package. The company was founded on October 15, 1949 and is headquartered in Icheon, South Korea.

SK Hynix Inc - ADR

SK Hynix is rebounding after a steep selloff in Korean and memory stocks, amid KOSPI volatility, foreign-investor selling and concerns about Chinese memory competition and the durability of AI spending. Bulls call the decline an overreaction given strong HBM demand and low valuations, while bears see risks from a normalizing memory cycle and continued sector pressure.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Morgan Stanley named Amazon a top pick and raised its AWS growth outlook, citing expected GPU deployments and expanding cloud demand, fueling the stocks sharp rally. Traders largely welcomed the upgrade but debated whether the move can hold, with some watching resistance and the upcoming earnings report for confirmation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Year-ender 2025 view on Indian pharma achievements

2025 felt like a quiet reset for Indian pharma. Exports and policy support remained important, but the more meaningful shift was in what people focused on inside companies and hospitals, said Saransh Chaudhary, president, global critical care, Venus Remedies and chief executive, Venus Medicine Research Center in a personal view on the Indian pharmaceutical sector.

Bad drugs or no drugs: Cancer patients face scary reality tied to foreign supply chain

… shelves of pharmacies rooted in the production of drugs in India … U.S., supplied by Intas Pharmaceuticals , failed one out of … us inside the oncology pharmacy where the drugs that save his … broken system. -- Intas Pharmaceuticals and Venus Remedies did not …

Ixigo And Venus Remedies Show Long-term Upside Potential: SEBI RA Gunjan Kumar 

Equity

The analyst eyes breakout opportunities in these two stocks, driven by their technical strength and growing institutional interest.

Big pharma pivoting to more lucrative obesity segment, Indian drugmakers eye insulin market

… or Sanofi , while one brand, Huminsulin by US-based pharma giant Eli Lilly , … care) of research-driven pharma company Venus Remedies. Innovative … case of small molecule drugs —have now hit the … “The entry of multiple pharmaceutical companies into this space …

Medivirs CEO to BioStock: I am proud to see our research contribute to a global solution

Antibiotic resistance is a growing global crisis, increasing the urgency for effective treatments. While Medivir now focuses on cancer therapies, it has a legacy in antimicrobial research. This was highlighted by Infex Therapeutics licensing agreement with Venus Remedies Ltd for the development of MET-X in India a compound developed from a research program that Medivir outlicensed in 2017. We reached out to Medivirs CEO Jens Lindberg for a comment. Read the interview with Jens Lindberg at biostock.se: https://www.biostock.se/en/2025/03/medivirs-ceo-i-am-proud-to-see-our-research-

India, EU to renew FTA negotiations

India and the European Union will this week take stock of their negotiations for an ambitious free trade deal and broadly firm up a new strategic agenda. Venus Remedies inks pact with UK firm New Delhi: Venus Remedies said it has joined hands with UK-based Infex Therapeutics for the development of MET-X, an inhibitor, to […]

Infex partners with Venus Remedies to develop MET-X in India

https://www.investing.com/news/company-news/infex-partners-with-venus-remedies-to-develop-metx-in-india-93CH-3888284

Venus Remedies Ltd. engages in the manufacture and trade of pharmaceutical products. Its products include analgesic, analgesic and antipyretic, anti diabetic, antibiotic, cardiac, disinfectant and antiseptic, gastro therapy, hand sanitizer, hormone, iron supplement, neurology, oncology, pain management, respiratory, skin care, stress reliever, urology, vitamins/minerals/nutrients, and wound management. The company was founded by Pawan Chaudhary on September 15, 1989 and is headquartered in Panchkula, India.

Venus Remedies Ltd.

Neutral Sentiment

SEBI-registered analyst <a href="https://stocktwits.com/STOCKCEPE">Gunjan Kumar</a> has flagged Ixigo and Venus Remedies as stocks with potential long-term growth.IxigoKumar noted that Ixigo is nearly debt-free and has seen increased investment from domestic institutional investors (DII) in the past quarter, signaling growing investor confidence.<stembedurl>https://stocktwits.com/STOCKCEPE/message/617962420</stembedurl>The analyst said the strong demand from Tier II and III cities, where Ixigo enjoys a 94% penetration rate, is fueling the company’s growth.The company is now ramping up investment in hotel bookings to boost revenue, inspired by the success of its competitors.With India’s travel market projected to reach $48 billion by 2027, supported by rising incomes and improved infrastructure, Ixigo is well-positioned for sustained growth, according to Kumar.Technically, the stock recently broke resistance, closing above ₹185 for the first time. Kumar suggests watching for a move above ₹192, with support at ₹169.On the financial front, it has reported record-high revenue and over 70% year-on-year sales growth since its IPO.Venus RemediesVenus Remedies has an attractive valuation, according to Kumar. The company exports to over 70 countries and operates in a sector poised for growth.<stembedurl>https://stocktwits.com/symbol/VENUSREM.NSE</stembedurl>India’s pharmaceutical industry is expected to reach $65 billion by 2024, growing at 10–12% annually, driven mainly by demand for generic drugs.Fundamentally, Venus Remedies is almost debt-free and recently posted its highest net profit in the last 13 quarters, with revenue figures in line with the same quarter the previous year.The analyst said that foreign institutional investors (FIIs) have steadily increased their stakes over the past four quarters, signaling growing confidence in the company’s long-term prospects.From a technical perspective, the stock has broken out of a multi-year resistance zone and successfully retested it.The analyst suggested watching for ₹475 on the upside, with support at ₹424 on a closing basis.For updates and corrections, email newsroom[at]stocktwits[dot]com.

(Photo credit should read INDRANIL MUKHERJEE/AFP via Getty Images)

Current Price	1,599.90
Prev Close	1,650.80
Open	1,650.00
Dividend Yield	1.21%
50-Day Moving Average	1,666.89
Beta	-0.01
Avg. Volume	27,482.38
PE Ratio	18.33

52-Week High	2,044.30
52-Week Low	432.10
Market Capitalization	21.95B
EPS (Annual)	76.90
Price to Book	3.21
Revenue Per Employee	5.02M

Feed

News

Sentiment

Fundamentals

Info

VENUSREM.NSE Fundamentals